US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

VictoryShares US Discovery Enhanced Volatility Wtd ETF

51.03

0.0000

Volume:- -

Turnover:- -

Market Cap:25.52M

PE:- -

High:51.03

Open:51.03

Low:51.03

Close:51.03

52wk High:51.03

52wk Low:51.03

Shares:500.00K

Float Shares:500.00K

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

Codex Genetics Partners with C2N Diagnostics to Introduce the PrecivityAD2™ Blood Test in Hong Kong, Facilitating Access to Innovative Alzheimer's Disease Diagnostics

Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/CSF/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSF\",,,,,undefined,":{"symbol":"CSF","market":"US","secType":"STK","nameCN":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","latestPrice":51.03,"timestamp":1787342400000,"preClose":51.03,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":500000,"shares":500000,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"08-21 16:00:00 EDT","open":51.03,"high":51.03,"low":51.03,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":51.03,"sharesOutstanding":500000,"nav":51.331892,"aum":25665950,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSF\",,,,,undefined,":{"symbol":"CSF","floatShares":500000,"roa":"--","roe":"--","lyrEps":0,"shares":500000,"dividePrice":0,"high":51.03,"amplitude":0,"preClose":51.03,"low":51.03,"week52Low":51.03,"pbRate":"--","week52High":51.03,"institutionHeld":0,"latestPrice":51.03,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":51.03,"prevYearClose":51.03,"prevWeekClose":51.03,"prevMonthClose":51.03,"prevQuarterClose":51.03,"fiveDayClose":51.03,"twentyDayClose":51.03,"sixtyDayClose":51.03},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSF\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-24","symbol":"CSF","reason":null,"defaultRemindTime":1745501400000,"announcedDate":"2025-04-23","type":"delisting","dateTimestamp":1745467200000},{"date":"2025-04-10","symbol":"CSF","amount":0.053873,"announcedDate":"2025-04-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-10","defaultRemindTime":1744291800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-11","payableDate":"2025-04-10","currency":"USD","dateTimestamp":1744257600000,"payDate":"2025-04-11"},{"date":"2025-03-10","symbol":"CSF","amount":0.09736,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-10","defaultRemindTime":1741613400000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-11","payableDate":"2025-03-10","currency":"USD","dateTimestamp":1741579200000,"payDate":"2025-03-11"},{"date":"2024-12-12","symbol":"CSF","amount":0.194215,"announcedDate":"2024-12-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-12","defaultRemindTime":1734013800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-13","payableDate":"2024-12-12","currency":"USD","dateTimestamp":1733979600000,"payDate":"2024-12-13"},{"date":"2024-11-07","symbol":"CSF","amount":0.016451,"announcedDate":"2024-11-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-07","defaultRemindTime":1730989800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-08","payableDate":"2024-11-07","currency":"USD","dateTimestamp":1730955600000,"payDate":"2024-11-08"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSF\",market:\"US\",,,undefined,":[{"executeDate":"2017-01-17","recordDate":"2017-01-19","paymentDate":"2017-01-20","value":0.0124628,"currency":"USD"},{"executeDate":"2017-02-14","recordDate":"2017-02-16","paymentDate":"2017-02-17","value":0.0180041,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-21","value":0.072161,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-19","value":0.02261,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-16","value":0.048374,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSF\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSF\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620228692","title":"Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620228692","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620228692?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:30","pubTimestamp":1773919800,"startTime":"0","endTime":"0","summary":"Health economics analysis highlights the economic burden of late-stage leptomeningeal metastases (LM) and the potential value of earlier diagnosis using CNSide as it enters U.S. commercializationHOUST","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3258891/0/en/Plus-Therapeutics-to-Present-New-Analysis-at-ISPOR-Showing-CNSide-May-Reduce-Leptomeningeal-Metastases-Healthcare-Costs-by-40.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128526141.USD","LABU","BK4581","CNS","BK4007","BK4137","HCSG","BK4585","BK4588","BK4135","CSF","BK4539","LU0029874061.USD","BK4202","XLV","BK4139","LENZ","NCI","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620825580","title":"Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620825580","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620825580?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:15","pubTimestamp":1773836100,"startTime":"0","endTime":"0","summary":"Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals wit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/18/3258138/0/en/Gain-Therapeutics-Presents-Additional-Clinical-and-Biomarker-Data-from-Phase-1b-Clinical-Study-of-GT-02287-and-Preclinical-Data-from-Novel-Chemical-Series-at-AD-PD-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PD","BK4023","GANX","BK4139","BK4588","BK4119","BK4212","BK4585","CSF","GT","BK4132","LU1169589451.USD","LU1169590202.USD","DDC","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620255389","title":"Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days","url":"https://stock-news.laohu8.com/highlight/detail?id=2620255389","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620255389?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:00","pubTimestamp":1773831600,"startTime":"0","endTime":"0","summary":"– ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear palsy – – ARV-102 was well tolerated across all dose levels following 28","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/18/3258013/0/en/Arvinas-Announces-Positive-Phase-1-Data-for-ARV-102-Showing-Greater-Than-50-LRRK2-Degradation-in-the-CSF-of-Patients-with-Parkinson-s-Disease-Treated-for-28-Days.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF","BK4023","LU1169589451.USD","LU1169590202.USD","BK4196","PSP","PD","MD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618601754","title":"Codex Genetics Partners with C2N Diagnostics to Introduce the PrecivityAD2™ Blood Test in Hong Kong, Facilitating Access to Innovative Alzheimer's Disease Diagnostics","url":"https://stock-news.laohu8.com/highlight/detail?id=2618601754","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618601754?lang=en_us&edition=fundamental","pubTime":"2026-03-10 09:33","pubTimestamp":1773106380,"startTime":"0","endTime":"0","summary":"HONG KONG, March 10, 2026 /PRNewswire/ -- Codex Genetics, a leading precision diagnostics company headquartered in Hong Kong, today announces a strategic collaboration with C2N Diagnostics , a global leader in in advanced brain health diagnostics.The partnership will introduce the PrecivityAD2 blood test to healthcare professionals across Hong Kong, enabling access to C2N's innovative technology that aids in the diagnosis of Alzheimer's disease.The PrecivityAD2 test is intended for individuals aged 50 years and older with signs or symptoms of cognitive impairment undergoing evaluation for Alzheimer's disease or other causes of cognitive decline. The PrecivityAD2 test detects the presence or absence of brain amyloid pathology, a key hallmark of Alzheimer's disease, and supports a clinician's diagnosis.\"Our collaboration with C2N reinforces Codex Genetics' commitment to advancing precision medicine and to improving access to cutting-edge diagnostic technologies in Hong Kong and the regio","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/codex-genetics-partners-with-c2n-diagnostics-to-introduce-the-precivityad2-blood-test-in-hong-kong-facilitating-access-to-innovative-alzheimers-disease-diagnostics-302708754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSF","CSF.AU","BK7141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614084111","title":"Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA","url":"https://stock-news.laohu8.com/highlight/detail?id=2614084111","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614084111?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:00","pubTimestamp":1772020800,"startTime":"0","endTime":"0","summary":"BOSTON, Feb.  25, 2026  (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq:TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/25/3244474/0/en/Tiziana-Life-Sciences-Announces-New-Biomarker-Data-Showing-Nasal-Foralumab-Downregulates-CSF-Inflammation-Upregulates-Neuroprotective-Pathways-and-Correlates-with-Reduced-Microglia.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0971096721.USD","LU1244550221.USD","LU0426417589.USD","LU1585245621.USD","LU1989772923.USD","BK4532","LU1162221912.USD","LU1791710400.SGD","LU2347655156.SGD","LU0557290698.USD","LU2133065610.SGD","LU0912757837.SGD","LU0158827781.USD","LU0795875169.SGD","LU0006306889.USD","LU2506951958.HKD","LU1244550494.USD","LU1043141396.HKD","LU0795875086.SGD","LU1074936037.SGD","LU2271345857.HKD","LU0158827948.USD","LU0823417653.USD","LU0950375773.USD","LU2506951875.HKD","LU2028103732.USD","LU0006061336.USD","LU2506952170.USD","BK4085","LU2506952097.USD","LU0225283273.USD","LU1720051108.HKD","LU2023251221.USD","CSF","LU1280957306.USD","BK4504","EA","LU0314104364.USD","LU1732799900.SGD","LU0882574139.USD","LU2111349929.HKD","LU1430594728.SGD","BK4533","LU1791710582.SGD","LU2089284900.SGD","LU2357305700.SGD","LU1043141123.HKD","LU1668664300.SGD","BK4588","LU0640476718.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":65,"code":"91000000","status":"200"}]}}